Approved policies, procedures and guidelines

• MU IBC Charter, revised 1-19-2023 (PDF)
• MU IBC conflict of interest policy, revised 6-19-2024 (PDF)
• MU IBC dual use research of concern (DURC), adopted 9-17-2015 (PDF)
• MU IBC guidance for working with SARS-CoV-2, adopted 3-8-2026 (PDF)
• MU IBC policy on toxins, revised 4-2-2026 (Word)
• MU IBC policy statement on human/nonhuman primate cell lines, revised 8-17-2023 (PDF)
• MU IBC policy statement on transgenic animals, revised 9-21-2023 (PDF)
• MU IBC core facility guidelines, revised 8-15-2024 (PDF)
• MU IBC policy statement on transgenic plants, revised 5-18-2023 (PDF)
• MU IBC policy on handling lentivirus, adenovirus and AAV-based vectors, revised 04-26-2023 (PDF)
• MU IBC human gene transfer trials serious adverse event reporting policy, adopted 11-21-2013 (PDF)
• MU IBC policy on IBC meeting minutes, revised 10-19-2023 (PDF)
• MU IBC policy on redacting IBC meeting minutes, adopted 2-16-2024 (PDF)
• MU IBC policy on receipt and transmission of public comments, adopted 2-16-2024 (PDF)
• MU IBC policy on voting, adopted 4-2-2026 (PDF)
• MU IBC policy on renewals, suspensions and terminations of protocols, revised 8-18-2022 (PDF)
• MU vaccination policy and surveillance guidelines, login required; approved by IBC 3-17-2022 (PDF)